A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept

Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.

NCT05181592 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Luspatercept + Darbepoetin in MDS

NCT07096297 ·Status: RECRUITING ·Phase: PHASE2

Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients

NCT04539236 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2

Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)

NCT01749514 ·Status: COMPLETED ·Phase: PHASE2

Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)

NCT02268383 ·Status: COMPLETED ·Phase: PHASE2

A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

NCT02631070 ·Status: COMPLETED ·Phase: PHASE3

Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions

NCT05384691 ·Status: RECRUITING ·Phase: PHASE2

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

NCT05181735 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

NCT00255346 ·Status: COMPLETED ·Phase: PHASE2

Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts

NCT05005182 ·Status: TERMINATED ·Phase: PHASE2

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

NCT01928537 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions

NCT04477850 ·Status: COMPLETED ·Phase: PHASE2

Three Dosing Schedules of Oral Rigosertib in MDS Patients

NCT02075034 ·Status: WITHDRAWN ·Phase: PHASE1

Biologically Focused Therapy of Treatment-Refractory MDS Patients

NCT05245032 ·Status: COMPLETED

Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

NCT02920541 ·Status: COMPLETED ·Phase: PHASE1

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

NCT04717414 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

NCT01904682 ·Status: COMPLETED ·Phase: PHASE2

A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome

NCT01497145 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

NCT04064060 ·Status: RECRUITING ·Phase: PHASE3

MInimal Residual Disease Adapted Strategy

NCT04934475 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

NCT07107126 ·Status: RECRUITING ·Phase: PHASE1

A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

NCT00724334 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

NCT03946670 ·Status: TERMINATED ·Phase: PHASE2

Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS

NCT04749355 ·Status: UNKNOWN ·Phase: PHASE2

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT01895842 ·Status: COMPLETED ·Phase: PHASE1